

IN THE CLAIMS

Please amend the claims as follows.

1-22. Canceled.


231. (currently amended) A method ~~for~~of activating a receptor, comprising bringing said receptor into contact with an amphiphilic drug-oligomer conjugate comprising a therapeutic compound conjugated to an oligomer, wherein the oligomer comprises a lipophilic moiety coupled with ~~to~~ a hydrophilic moiety.
242. (currently amended) The method of claim 181, further characterized in that said conjugate exhibits activity ~~in~~ without cleavage of the therapeutic compound from the oligomer.
253. (currently amended) The method of claim 181, wherein the receptor is a G-protein coupled receptor.
264. (currently amended) The method of claim 181, wherein the receptor is an Opioid opioid receptor.
275. (currently amended) The method of claim 181, wherein the receptor is a Opioid an opioid receptor; selected from the group consisting of δ , μ , and κ .
286. (currently amended) The method of claim 181, wherein the hydrophilic moiety is selected from the group consisting of sugar and PEG₁₋₇.
297. (currently amended) The method of claim 181, wherein the hydrophilic moiety is

selected from the group consisting of fatty acid, alkyl 1-26, cholesterol and adamantane.

308. (currently amended) The method of claim 181, wherein the therapeutic compound is a peptide having an added N-terminal residue selected from the group consisting of proline, and alanine.
319. (currently amended) The method of claim 181, wherein the therapeutic compound is a peptide or protein.
3210. (currently amended) The method of claim 181, wherein the therapeutic compound is a peptide and the peptide is selected from the group consisting of: enkephalin, adrenocorticotropic hormone, adenosine deaminase, ribonuclease, alkaline phosphatase, angiotensin, antibodies, arginase, arginine deaminatease, asparaginase, caerulein, calcitonin, chymotrypsin, cholecystokinin, clotting factors, dynorphins, ~~endorphins~~, endorphins, enkephalins, ~~enkephalins~~, erythropoietin, gastrin-releasing peptide, glucagon, hemoglobin, hypothalamic releasing factors, interferon, katacalcin, motilin, neuropeptide Y, neurotensin, non-naturally occurring opioids, ~~oxytocin~~oxytocin, papain, parathyroid hormone, peptides prolactin, soluble CD-4, somatomedin, somatostatin, ~~somatostatin~~, somatotropin, superoxide dismutase, thyroid stimulating hormone, tissue plasminogen activator, trypsin, vasopressin, and analogues and active fragments of such peptides.
3311. (currently amended) The method of claim 181, wherein the amphiphilic oligomer is selected from the group consisting of:



wherein n=3 to 25 and m=1 to 6;



wherein n=3 to 25 and m=1 to 7;




wherein n=3 to 25, m=1 to 7 and X=O or N;




wherein m=0 to 5 and R=cholesterol or adamantan;~~or~~



wherein m=0 to 5;



wherein m=0 to 7; and



wherein m=1 to 7 and X=N or O.

3412. (currently amended) The method of claim 481, wherein the hydrophilic moiety is coupled to the hydrophobic moiety by a hydrolyzable bond.

3513. (currently amended) The method of claim 481, wherein the hydrophilic moiety is

coupled to the hydrophobic moiety by a non-hydrolyzable bond.

36-63. Canceled.

6414. (new and currently amended) The method of claim 1, wherein the therapeutic compound is an opioid receptor agonist, antagonist or partial agonist/partial antagonist.

6515. (new and currently amended) The method of claim 1, wherein the therapeutic compound is an enkephalin.